These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10958594)

  • 1. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
    Chidiac T; Budd GT; Pelley R; Sandstrom K; McLain D; Elson P; Crownover R; Marks K; Muschler G; Joyce M; Zehr R; Bukowski R
    Invest New Drugs; 2000 Aug; 18(3):253-9. PubMed ID: 10958594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
    Skubitz KM
    Cancer Invest; 2003 Apr; 21(2):167-76. PubMed ID: 12743981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
    Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas.
    Garcia AA; Kempf RA; Rogers M; Muggia FM
    Ann Oncol; 1998 Oct; 9(10):1131-3. PubMed ID: 9834828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
    Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
    Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
    El-Rayes BF; Ibrahim D; Shields AF; LoRusso PM; Zalupski MM; Philip PA
    Invest New Drugs; 2005 Jan; 23(1):57-62. PubMed ID: 15528981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.
    James ND; Coker RJ; Tomlinson D; Harris JR; Gompels M; Pinching AJ; Stewart JS
    Clin Oncol (R Coll Radiol); 1994; 6(5):294-6. PubMed ID: 7530036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.
    ten Hagen TL; Seynhaeve AL; van Tiel ST; Ruiter DJ; Eggermont AM
    Int J Cancer; 2002 Jan; 97(1):115-20. PubMed ID: 11774252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
    Hubert A; Lyass O; Pode D; Gabizon A
    Anticancer Drugs; 2000 Feb; 11(2):123-7. PubMed ID: 10789595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
    Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
    Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of liposomal doxorubicin in advanced gynecologic cancers.
    Israel VP; Garcia AA; Roman L; Muderspach L; Burnett A; Jeffers S; Muggia FM
    Gynecol Oncol; 2000 Aug; 78(2):143-7. PubMed ID: 10926793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
    Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
    Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
    Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
    Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.